 |
 |
 |
 |
 |
 |
|
||||||||||||||
SELECT PUBLICATIONS
Boccardo F et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23(22):5138-47. Abstract
Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract
Fisher B et al. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: Updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 2004;96(24):1823-31. Abstract
Fisher B et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997;89(22):1673-82. Abstract
Goldhirsch A et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16(10):1569-83. Abstract
Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Howell A et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract
Jakesz R et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract
Petrek JA et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 2006;24(7):1045-51. Abstract
Petrek JA et al. Time course and determinants of menstrual bleeding after breast cancer treatments: A prospective study. Proc ASCO 2005;Abstract 538.
Punglia RS et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: A decision analysis. J Clin Oncol 2005;23(22):5178-87. Abstract
Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006;11(5):422-34. Abstract
Sukumvanich P et al. Incidence and time course of bleeding after long-term amenorrhea following breast cancer treatment: A prospective study. Proc ASCO 2005;Abstract 575.
Thürlimann BJ for the BIG 1-98 Collaborative. Letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. IBCSG 18-98/BIG 1-98. Presentation. ASCO 2005;Abstract 511.
| Table of Contents | Top of Page |
Editor:
Neil Love, MD
Interviews
Monica Morrow, MD
- Select publications
Kevin R Fox, MD
- Select publications
Thomas B Julian, MD
- Select publications
Robert W Carlson, MD
- Select publications
Richard M Elledge, MD
- Select publications
 |
 |
 |
 |
 |
